Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07049328 · ClinicalTrials.gov registry record · Phase 1
HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata
A Phase 1 study of Alopecia Areata(AA), sponsored by HCW Biologics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT07049328 is a Phase 1 study of Alopecia Areata(AA) that is actively recruiting participants, run by HCW Biologics. The registered enrollment target is 30 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT07049328, a Phase 1 study of Alopecia Areata(AA), is actively recruiting participants, sponsored by HCW Biologics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
Conditions Studied
Interventions
- DRUG HCW9302, an IL-2 fusion protein
Study Locations (2)
Florida
- James A. Haley Veterans' Hospital - Tampa
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-08-16 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07049328
The ClinicalTrials.gov registry entry for NCT07049328 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HCW Biologics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alopecia Areata(AA) appearing as the primary indexed condition, and to 1 intervention - of which HCW9302, an IL-2 fusion protein is the first listed.
NCT07049328 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT07049328 about?
NCT07049328 is a clinical study titled "HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata". This is a Phase 1, open-label, multi-center, competitive enrollment, and dose-escalation study of HCW9302 in subjects with Alopecia Areata (AA)
What is the current status of trial NCT07049328?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-08-16. Estimated completion is 2026-12-15.
What conditions does trial NCT07049328 study?
This clinical trial studies the following conditions: Alopecia Areata(AA).
What interventions are being tested in trial NCT07049328?
The interventions under investigation include: HCW9302, an IL-2 fusion protein (DRUG).
Who is sponsoring clinical trial NCT07049328?
This trial is sponsored by HCW Biologics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07049328 being conducted?
This trial has 2 study locations across Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.